Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910505 | 0.82 | CCR2 (0.48) | CCR2PTGER4POLB | |
| SCHEMBL4912893 | 0.81 | ALDH1A1 (0.51) | CCR2PTGER4ABL1KDM4ECYP1A2 | |
| SCHEMBL3155237 | 0.81 | TDP1 (0.42) | ABL1SRCJAK1TYK2RAB9A | |
| SCHEMBL305726 | 0.80 | MEN1 (0.48) | CCR2PTGER4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4902844 | 0.79 | L3MBTL1 (0.43) | CCR2PTGER4ABL1KDM4ECYP1A2 | |
| SCHEMBL305881 | 0.78 | HTR1A (0.43) | CCR2PTGER4SCN9ACYP1A2CYP3A4 | |
| SCHEMBL4911339 | 0.76 | L3MBTL1 (0.54) | CCR2PTGER4ABL1RAB9A | |
| SCHEMBL4912482 | 0.76 | CCR2 (0.85) | CCR2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL305125 | 0.75 | POLB (0.44) | CCR2ABL1SRCPOLBMAPK7 | |
| SCHEMBL4909330 | 0.74 | ALDH1A1 (0.48) | CCR2PTGER4ABL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | CCR2, CCR1, CCRL2 | CCR2 1/4885PTGER4 343/4885ABL1 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.